FDA deadline for user fee layoffs is uncertain, GAO tells Senate Labor Committee.
FDA USER FEE CARRY-OVER EFFECT ON OPERATIONS UNCERTAIN, GAO SAYS in a report to Senate Labor & Human Resources Committee Chairman Jeffords (R-Vt.) released Aug. 5. "Because FDA has developed only very preliminary estimates for the cost of closing down the user fee program...it is not possible to estimate how long FDA could continue operations into fiscal year 1998 using funds carried over from fiscal year 1997," the General Accounting Office said in the July 21 report.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth